Morgan Stanley Downgrades Atea Pharmaceuticals (AVIR) to Underweight
Tweet
Share
E-mailGet Alerts AVIR Hot Sheet
Price: $3.73 --0%
Rating Summary:
2 Buy, 1 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 3 | New: 4
Rating Summary:
2 Buy, 1 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 3 | New: 4
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison downgraded Atea Pharmaceuticals (NASDAQ: AVIR) from Equalweight to Underweight with a price target of $7.00.
For an analyst ratings summary and ratings history on Atea Pharmaceuticals click here. For more ratings news on Atea Pharmaceuticals click here.
Shares of Atea Pharmaceuticals closed at $8.30 yesterday.
You May Also Be Interested In
- Citi Upgrades Sirius XM Radio (SIRI) to Neutral, 'risk-reward is balanced at prevailing levels'
- Morgan Stanley Downgrades Innolux Corp. (3481:TT) to Equalweight
- Oppenheimer Downgrades MSCI Inc. (MSCI) to Perform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
